<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01627132</url>
  </required_header>
  <id_info>
    <org_study_id>SHSG-01</org_study_id>
    <nct_id>NCT01627132</nct_id>
  </id_info>
  <brief_title>Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial</brief_title>
  <official_title>Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shimousa Hematology Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Epidemiological and Clinical Research Information Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shimousa Hematology Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether dasatinib can be discontinued without
      occurrence of molecular relapse in patients with chronic myeloid leukemia in chronic phase in
      complete molecular remission (CMR) while on dasatinib.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The overall probability of maintenance of complete molecular remission at 12 months after stopping dasatinib.</measure>
    <time_frame>at 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of complete molecular remission that will be sustained after dasatinib rechallenge.</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>dasatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>100mg QD</description>
    <arm_group_label>dasatinib</arm_group_label>
    <other_name>BMS-354825</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic Myeloid Leukemia in the Chronic Phase.

          -  Patients with BCR-ABL-negative checks.

          -  15 years old over.

          -  ECOG performance status (PS) score 0-2.

          -  Adequate organ function (hepatic, renal and lung).

          -  Signed written informed consent.

        Exclusion Criteria:

          -  A case with the double cancer of the activity.

          -  Women who are pregnant or breastfeeding.

          -  Patients with complications or a history of severe.

          -  Patients with mutation of T315I、F317L、V299L.

          -  Patients with additional chromosome abnormalities.

          -  The case of Pleural effusion with poor control.

          -  Patients with a history of hematopoietic stem cell transplantation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koiti Inokuchi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nippon Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Koiti Inokuchi, MD,PhD</last_name>
    <phone>+81(0)3-3822-2131</phone>
    <email>inokuchi@nms.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nippon Medical School</name>
      <address>
        <city>Sendagi 1-1-5</city>
        <state>Bunkyo-ku,Tokyo</state>
        <zip>113-8603</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koiti Inokuchi, MD,PhD</last_name>
      <phone>+81(0)3-3822-2131</phone>
      <email>inokuchi@nms.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Hisashi Wakita, MD,PhD</last_name>
      <phone>+81(0)476-22-2311</phone>
      <email>wakita@naritasekijuji.jp</email>
    </contact_backup>
    <investigator>
      <last_name>Koiti Inokuchi, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2012</study_first_submitted>
  <study_first_submitted_qc>June 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2012</study_first_posted>
  <last_update_submitted>June 22, 2012</last_update_submitted>
  <last_update_submitted_qc>June 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shimousa Hematology Study Group</investigator_affiliation>
    <investigator_full_name>Koiti Inokuchi,MD,PhD.</investigator_full_name>
    <investigator_title>Nippon Medical School</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

